Overview
New PET tracers target specific molecular pathways to improve disease detection. These tracers expand applications beyond standard metabolic imaging. Clinical translation requires validation and regulatory approval.
Clinical Uses
Targeted tracers enable imaging of receptors inflammation and cellular processes. They improve specificity for oncologic and neurologic indications. Tracer selection depends on the clinical question and availability.
Production and Logistics
Radiochemistry and distribution affect tracer accessibility and scheduling. Short half life tracers require local production or rapid transport. Infrastructure investment supports broader clinical use.
Future Directions
Novel tracers paired with hybrid imaging enhance precision medicine. Quantitative PET metrics support therapy selection and monitoring. Ongoing trials will define clinical roles and cost effectiveness.